
==== Front
Pain Ther
Pain Ther
Pain and Therapy
2193-8237
2193-651X
Springer Healthcare Cheshire

39126594
640
10.1007/s40122-024-00640-3
Review
Identifying and Evaluating Biological Markers of Postherpetic Neuralgia: A Comprehensive Review
http://orcid.org/0000-0001-9269-5644
Li Yunze 1
Jin Jiali 1
Kang Xianhui 2
http://orcid.org/0000-0003-0962-9449
Feng Zhiying fzy1972@zju.edu.cn

1
1 https://ror.org/05m1p5x56 grid.452661.2 0000 0004 1803 6319 Department of Pain Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003 Zhejiang China
2 https://ror.org/05m1p5x56 grid.452661.2 0000 0004 1803 6319 Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang China
10 8 2024
10 8 2024
10 2024
13 5 10951117
6 5 2024
11 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Postherpetic neuralgia (PHN) manifests as persistent chronic pain that emerges after a herpes zoster outbreak and greatly diminishes quality of life. Unfortunately, its treatment efficacy has remained elusive, with many therapeutic efforts yielding less than satisfactory results. The research to discern risk factors predicting the onset, trajectory, and prognosis of PHN has been extensive. However, these risk factors often present as nonspecific and diverse, indicating the need for more reliable, measurable, and objective detection methods. The exploration of potential biological markers, including hematological indices, pathological insights, and supportive tests, is increasing. This review highlights potential biomarkers that are instrumental for the diagnosis, management, and prognosis of PHN while also delving deeper into its genesis. Drawing from prior research, aspects such as immune responsiveness, neuronal injury, genetic makeup, cellular metabolism, and pain signal modulation have emerged as prospective biomarkers. The immune spectrum spans various cell subtypes, with an emphasis on T cells, interferons, interleukins, and other related cytokines. Studies on nerve injury are directed toward pain-related proteins and the density and health of epidermal nerve fibers. On the genetic and metabolic fronts, the focus lies in the detection of predisposition genes, atypical protein manifestations, and energy-processing dynamics, with a keen interest in vitamin metabolism. Tools such as functional magnetic resonance imaging, electromyography, and infrared imaging have come to the forefront in the pain signaling domain. This review compiles the evidence, potential clinical implications, and challenges associated with these promising biomarkers, paving the way for innovative strategies for predicting, diagnosing, and addressing PHN.

Keywords

Postherpetic neuralgia
Biomarkers
Neuroinflammation
Functional magnetic resonance
Zhejiang Provincial Natural Science Foundation of China LQ22H090022 Li Yunze http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82271239 Feng Zhiying Key R&D Program of Zhejiang2022C03081 Feng Zhiying issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2024
==== Body
pmcKey Summary Points

This review aims to identify key biomarkers linked to immune activity, genetic predispositions, neuron integrity, metabolism, and pain pathways to improve the diagnosis, treatment, and prediction of postherpetic neuralgia (PHN), thereby enhancing patient quality of life.	
Challenges such as high analysis cost, limited sample sizes, and lack of universal cohorts may constrain biomarker integration into clinics.	
Future studies with large cohorts will be required to find move effective biomarkers and develop precise predictive models for personalized PHN treatment.	

Introduction

Herpes zoster (HZ), commonly referred to as shingles, is an illness triggered by the reactivation of the varicella-zoster virus (VZV). It predominantly manifests as pain and rashes that follow the nerve pathways. Pain, often described as burning, cutting, stabbing, or resembling electric shocks, is usually accompanied by severely intense hypersensitivity. The incidence rate of HZ is approximately 0.523–1.09% annually. While most patients experience pain alleviation and convalescence within weeks, between 5 and 30% of patients may progress to postherpetic neuralgia (PHN) [1]. Currently, first-line treatments for PHN in clinical practice include antiepileptic drugs and tricyclic antidepressants, but their efficacy is often suboptimal, or their side effects are intolerable [2]. The course of PHN can extend over several years or decades, with persistent intense pain causing immense distress to patients. This significantly impairs quality of life and productivity, possibly resulting in insomnia, anxiety, depression, and potentially suicide [3].

The cornerstone of PHN prevention hinges on the identification of high-risk individuals via effective strategies, enabling early and standardized interventions [4]. At present, the primary determinants of PHN risk are discerned via clinical indications, despite their broad diversity and lack of specificity. This underscores the pressing clinical need for more reliable, objective, and measurable biomarkers to facilitate accurate prevention. The purpose of this review is to detail the latest research progress on PHN biomarkers evaluated through hematological and pathological tests and auxiliary examinations [5, 6]. This approach might enable early PHN detection, thereby averting catastrophic outcomes.

Postherpetic Neuralgia

Following initial infection with VZV, children typically develop chickenpox. Even after recovery, the virus may remain dormant in various areas, such as the spinal dorsal root ganglia. Reactivation of this dormant VZV can occur when immune responses are compromised due to various factors, leading to expansive viral replication. This can result in the virus traveling along nerve fibers to the skin, causing rashes. Concurrently, the activation of local immune-inflammatory responses may cause rashes, destruction of nerve fiber endings, and increased nerve fiber sensitivity, resulting in hyperalgesia and touch-induced pain [7].

Clinical Risk Factors for Postherpetic Neuralgia

Currently, the clinical prediction of PHN is largely based on a variety of patient attributes and factors associated with shingles. These include age, sex, prodromal symptoms, and the severity of acute pain during the initial infection stages [8]. Additionally, factors such as touch-induced pain, numbness, interference with daily life, the severity and extent of the rash, the presence of rashes in specific areas (e.g., eyes, perineum), and severe immunosuppression (e.g., human immunodeficiency virus [HIV] infection, new tumors, high-dose hormone therapy, hematopoietic stem cell transplantation, hematologic malignancies, systemic lupus erythematosus, inflammatory bowel disease) have been identified as potential indicators of PHN development [9, 10]. Furthermore, certain conditions, including surgery, trauma at the site of infection, tumor growth, tuberculosis, hepatitis B infection, hypertension, diabetes, coronary heart disease, angina, smoking, and alcohol addiction, have been identified as risk factors for PHN [11, 12].

Numerous pain centers have used extensive datasets to construct predictive models for the incidence of PHN [13–16]. In our research, we specifically developed a predictive model to evaluate the success of pulsed radio-frequency therapy in mitigating herpes zoster neuralgia [17]. Notably, our model identified various risk factors for PHN development, including male sex, extended duration of herpes zoster infection, higher doses of pregabalin, a higher 36-Item Short Form Health Survey (SF-36) somatic pain index score, a lower peripheral blood lymphocyte count, and decreased levels of low-density lipoprotein and complement C4. Upon the analysis of these findings, we successfully formulated a predictive model.

The discrepant methodologies of different clinical observation items, coupled with sample size variations and regional differences, have given rise to inconsistent results and differing weights for high-risk factors. Consequently, the research findings have yet to reach a uniform consensus. For instance, some research studies have shown that females younger than 60 years have a greater risk of PHN and females older than 60 years have a lower risk of PHN than males of the same age [18]. Consequently, these clinical high-risk factors exhibit low sensitivity and a notable measure of uncertainty, which hampers their clinical value. Therefore, the identification of more sensitive biomarkers is imperative.

Biomarkers for Postherpetic Neuralgia

The consistent escalation in the use of reliable biomarkers, including blood tests, pathological evaluations, and additional diagnostic methods, is currently leveraged to identify high-risk populations [5, 6]. These advancements have significantly enhanced the ability to predict PHN. The biomarkers identified in this discussion (Fig. 1) span a broad spectrum, covering immune cell variations, cytokines, blood proteins, genetic and DNA expression analyses, proteomics and metabolomics studies, epidermal nerve fiber counts, functional magnetic resonance imaging (fMRI) and electromyography evaluations, and infrared thermographic techniques, among others.Fig. 1 Potential biomarkers for postherpetic neuralgia

Immunological Biomarkers

Immune Cells

Upon reactivation of VZV, dendritic cells (DCs) detect the virus, leading to upregulation of major histocompatibility complex (MHC) class I and II proteins. This event triggers the release of substantial inflammatory factors. Consequently, natural killer (NK) cells, along with VZV-specific T cells, are activated, facilitating the infiltration of CD4+ and CD8+ T cells, which causes ganglion necrosis. Decreased immunity mediated by VZV-specific T cells is associated with the onset of HZ. Postherpetic ganglioneuritis and persistent infiltration of CD8+ T cells can amplify the response to benign stimuli over an extended period (Fig. 2) [19, 20]. Extensive studies have investigated the role of immune cells as biological markers for PHN, and several key findings are presented here.Fig. 2 Pathogenesis of postherpetic neuralgia. The mechanism of action of immune cells in postherpetic neuralgia (A). The self-destruction of skin cells and fibroblasts driven by viruses leads to the appearance of rashes. Concurrently, immune-inflammatory actions stimulate peripheral nerve endings and amplify their sensitivity, thereby inducing intense pain and heightened sensitivity to touch. Post-VZV reactivation, MHC class I and II protein levels increase, and both CD4+ and CD8+ T cells invade the ganglia, causing tissue death and bleeding. The onset of HZ has been linked to a decrease in the VZV-specific defense provided by T cells. The pathogenesis of postherpetic neuralgia (B). After damage to peripheral nerves occurs, the expression of voltage-gated sodium channels and the function and expression of transient receptor potential channels are altered in the injured sensory nerve fibers. These changes lead to increased spontaneous activity, rendering the nerves hyperexcitable and resulting in allodynia and hyperalgesia, common symptoms of PHN. On the central side, a sustained barrage of atypical nerve impulses from the periphery drives central sensitization. This results in enhanced responsiveness to both painful and non-painful stimuli. ACC anterior cingulate cortex, DRG dorsal root ganglion, HZ herpes zoster, MHC major histocompatibility complex, NK natural killer, PFC prefrontal cortex, PHN postherpetic neuralgia, S1 primary somatosensory cortex, VZV varicella-zoster virus

Neutrophil-to-Lymphocyte Ratio

The diminished functionality of the immune system, attributable to immune cells, serves as a definitive risk factor for the occurrence of HZ and PHN. The neutrophil-to-lymphocyte ratio (NLR) is commonly used to assess lymphocyte function in clinical settings. Studies of patients with rheumatic conditions have shown an increase in the NLR among those infected with HZ [21]. Furthermore, research conducted on patients who underwent liver transplants suggested a close correlation between a patient’s preoperative NLR and susceptibility to HZ and PHN [22]. Investigations into Ramsay Hunt syndrome illustrated that patients with a relatively high NLR presented significantly elevated grades of House–Brackmann (HB) facial paralysis, subsequently diminishing the likelihood of complete recovery [23]. The efficacy of minimally invasive treatment for PHN is pervasively influenced by a decrease in lymphocyte count; changes in the number and proportion of lymphocytes directly impact both the occurrence of PHN and the effectiveness of interventions [17]. An increased NLR is associated with an increase in neutrophils and a decrease in lymphocytes; a reduced lymphocyte count generally signifies impaired cell-mediated immune function, while an increase in neutrophils translates to an enhanced systemic inflammatory response. The activation of neutrophils may suppress T-cell proliferation and cytotoxic behaviors by binding PD-L1 in neutrophils to PD-1 in T cells, resulting in immune suppression [24]. Aberrations in the NLR can offer insightful and critical data for predicting the progression and prognosis of both HZ and PHN.

T Cells and Subtypes

Notably, patients suffering from HZ neuralgia exhibit diminished cell-mediated immune function, evidenced principally by T-lymphocyte dysfunction. An increase in HZ infections among patients with COVID-19 has prompted researchers to suspect a potential connection to T cell dysfunction—characterized by a decrease in cell volume and functional exhaustion—induced by the novel coronavirus [25]. Studies of T-lymphocyte subclasses in patients with HZ revealed a decrease in the numbers of CD3+ T cells and CD8+ T cells with aging and during the development of PHN [26]. Intriguingly, prior to the traditional manifestation of HZ, a decreasing ratio of T-cell subgroups (CD4+ T/CD8+ T cells) was observed. However, this ratio increases after the emergence of rashes and returns to normal once the lesions disappear. This pattern suggests that an immune imbalance is a potential catalyst for viral activation [27]. A study comprising 76 patients with HZ discerned an inverse relationship between CD4+ T lymphocytes and the severity of pain: the more severe the pain, the more significant the reduction in lymphocytes [28]. This finding indicates an impairment of T-cell immunity predominantly in severe cases of HZ. Moreover, the study revealed a substantial increase in the proportion of regulatory T cells (Tregs) in patients with HZ, which could suppress the immune response to antiviral CD4+ T cells due to increased Treg cell activation. Scrutinizing the number of T cells and their immune functions could serve as indicators of the risk of PHN development. A decrease in the number of T cells and inhibition of their function could cause an HZ outbreak, potentially leading to chronic disease and, notably, PHN sequelae.

VZV-specific cell-mediated immunity (VZV-CMI) is recognized for its vital role in activating T cells that combat VZV, which results in efficient virus elimination. HZ originates from a decrease in VZV-specific T-cell immunity, often consequent to aging or immune suppression. This causes reactivation of the latent VZV within the sensory ganglia [29]. In the skin, VZV-specific T cells selectively infiltrate and remain at the rash site compared to the opposing site [30]. Further support for this viewpoint comes from the detection of VZV DNA and proteins in the peripheral blood mononuclear cells (PBMCs) of patients suffering from PHN. Taken together, these findings suggest that low-level viral ganglionitis contributes to PHN and heightens the chance of prolonged viral infection, possibly extending months beyond the clinical remission of HZ [31]. In contrast, patients with diminished VZV-CMI often exhibit persistent VZV DNA detection in saliva and are more susceptible to PHN [32]. These patients struggle to control viral replication and may undergo persistent viral shedding, facilitating the onset of PHN. In elderly individuals, increased age or depletion of VZV-specific T cells in PBMCs results in a degraded effector T-cell response to HZ [33]. Treg cells accumulate at the infection sites in elderly individuals and could further suppress the activity of other functionally normal VZV-specific T cells, thereby encouraging PHN development [34]. These findings support current strategies for formulating new shingle vaccines designed to stimulate cell-mediated immunity, prevent VZV reactivation, and avoid the development of shingles and PHN. An initial poor response of VZV-specific T cells or persistent VZV presence in saliva could serve as diagnostic markers, thereby paving the way for more precise treatment plans for high-risk patients with PHN.

Comprehensive Immune Cell Atlas

As detection technology and accuracy continually evolve, the classification of immune cell types becomes increasingly granular, inevitably enhancing the sensitivity and specificity of PHN predictions. Our research group systematically employed cytometry by time-of-flight (CyTOF) technology in previous studies to examine the temporal changes in all immune cell subgroups in the peripheral blood of patients with HZ-related neuropathic pain. We characterized and analyzed the dynamic changes in six primary immune cell clusters, namely, CD4+ T cells, CD8+ T cells, γδ T cells, NK cells, B cells, and myeloid cells [6]. Our findings indicated diverse rhythmic alterations over time, revealing patterns of rapid and slow responses. Primarily, the changes in T cells were most notable, as evidenced by the decreasing ratio of CD4+/CD8+ T cells. Further investigation of 40 immune cell subclusters revealed that the T02, T03, T10, T18, and T25 clusters were significantly greater in patients with PHN than in those experiencing pain relief. Concurrently, the levels of tumor necrosis factor alpha (TNF-α) produced by cells in the T02 and T18 clusters and other immune cell subgroups, as well as VZV-specific T cells, were greater than those in patients who did not progress to PHN. All T-cell subgroups with slow response patterns were negatively correlated with clinical pain-related scores. The T02 and T18 clusters in patients who experienced pain relief (the non-PHN group) were significantly greater than those of patients with PHN. Moreover, we found that in patients with PHN, the levels of PD-1+ CD4+ T cells, VZV-specific PD-1+ CD4+ T cells, and TNF-α produced by VZV-specific T cells were greater than those in patients without PHN. However, confirming the predictive ability of these markers requires extensive large-scale data validation.

Other Immune Cells

NK cells, intrinsic cytotoxic lymphocytes, play a pivotal role in antiviral immunity and are particularly evident in VZV infections. Individuals with NK cell deficiencies often exhibit heightened vulnerability to intense, sometimes lethal, VZV infections [20]. A decrease in both NK cell and VZV-specific T-cell populations indicates an increased risk for VZV resurgence, culminating in shingles [19]. Frequent HZ infections are reported among kidney transplant recipients receiving prolonged immunosuppressive therapy, and the long-term HZ prevalence in these patients correlates directly with NK cell counts measured 6 months post-transplant [35].

DCs, specialized antigen-presenting cells, act as pivotal immune actors during viral incursions, orchestrating the onset and regulation of antiviral immune responses. Recorded evidence indicates successful VZV infection of both immature and mature monocyte-derived DCs, Langerhans cells (LCs), and plasmacytoid dendritic cells (pDCs) [36]. Monocytes and macrophages are paramount for recognizing pathogens, bolstering immune defense, and orchestrating inflammation resolution. Monocyte invasion and microglial proliferation often coincide with demyelination [37]. Acute ganglia infections exhibit nuclear inclusions, viral antigens, and VZV entities. Moreover, the connection between VZV viremia and both primary VZV infection and reactivation was confirmed by identifying interactions between monocytes and VZV during these phases.

Cytokines

The interplay between proinflammatory and anti-inflammatory cytokines critically shapes the mechanisms involved in neuropathic pain [38]. Proinflammatory cytokines, including TNF-α, interferon gamma (IFN-γ), interleukin (IL)-1β, and IL-17, can directly or indirectly intensify neuronal excitability and attenuate pain thresholds by stimulating signaling pathways within neurons, glial cells, and immune cells, subsequently leading to pain genesis. In contrast, anti-inflammatory cytokines such as IL-10 and IL-4 alleviate pain through the activation of specific pathways, including the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, while concurrently impeding the release of proinflammatory cytokines. Current research on immune–neuromolecular interactions emphasizes the imbalance of inflammatory factors in patients with neuropathic pain.

IFN, a key antiviral defense and regulatory factor within the immune system, has significant implications for patients with primary immunodeficiencies characterized by defects in IFN signaling pathways, which increase susceptibility to acute VZV infection. Rare downstream genetic defects in the type I IFN signaling pathway heighten susceptibility to varicella and other viral infections [39]. VZV-encoded genes can limit type I IFN production, thus regulating the signal transduction of type I IFN [40, 41]. This diminished function is partly due to the inhibition of intrinsic function and the presence of autoantibodies. Of five PHN test subjects who tested positive for antibodies against cellular cytokines, three had antibodies against IFN-α [42]. In vitro studies revealed that IFNs significantly curtail VZV transcription and virus propagation by inhibiting the replication ability of VZV in cultured human neurons [43]. Notably, dorsal root ganglion injections of IFN-α2b can alleviate pain and reduce the incidence of PHN, as evidenced by long-term follow-up [44]. Further research into IFN subtypes revealed that patients with PHN exhibited distinctly greater expression of IFN-A1/13 and IFN-A2 than the control group and greater expression of IFN-4 and IFN-10 than the HZ group [45]. The use of specific IFN tests could identify a cohort of high-risk patients with PHN with increased IFN expression, allowing for targeted therapy to alleviate IFN expression and prevent the onset of PHN.

In the acute phase, serum levels of the IL-6 protein were elevated in patients who subsequently developed PHN, and this elevation was positively correlated with pain severity [46]. Furthermore, patients suffering from severe VZV infection exhibited a significant increase in serum IL-6 levels, which were positively correlated with the effectiveness of treatment for shingles-related pain [47]. These observations suggest that serum IL-6 levels during the acute phase of shingles could serve as a reflection of disease severity and are closely related to pain intensity and prognosis, thus playing a key role in the onset of PHN. It was also found that serum IL-10 levels increased significantly in patients with severe VZV infection, suggesting that it is a potential predictive factor for PHN duration. The origin of IL-10 in the serum has not been determined; however, Treg cells are a potential source of IL-10 [48]. Furthermore, a comparative study revealed a considerable increase in the proportion of Treg cells within the CD4+ T cells in patients with acute HZ in comparison to healthy controls [28]. An early increase in serum IL-10 levels could be an essential biological marker for PHN manifestation. Elevated levels of IL-18 were also observed in patients with HZ and were correlated with the intensity of rash and pain [49]. Genome-wide association studies (GWAS) of two different IL-18 proteins revealed a correlation between the predicted increase in IL-18 protein levels and increased susceptibility to PHN. Consequently, these findings suggest that increased IL-18 protein levels may amplify the risk of PHN, which could contribute to the development of new prevention and treatment strategies for PHN [50].

Differences across these studies may result from individual differences or variations in disease onset stage. Notably, PHN onset typically involves a collection of cytokines, and the lack of a reliable multi-cytokine predictive model underscores the need for additional research and the use of big data to develop accurate prediction models. Current cytokine detection methods have limitations, especially in detecting and analyzing rare cytokines. However, with rigorous research, the development of multi-cytokine predictive models and personalized prediction models accounting for individual clinical presentations, and increased analysis of specific cytokine subtypes, cytokines have the potential to revolutionize PHN prediction.

Nerve Injury-Related Proteins

Certain proteins associated with neurotrauma may function as novel predictors of related neurological disorders. Accordingly, numerous research efforts have been directed toward exploring the prospective predictive value of these specific circulatory biomarkers of neuronal injuries for PHN. A key protein being studied is neuron-specific enolase (NSE). Given that nerve damage results in its prolific release, NSE concentration has emerged as a barometer for the severity and future trajectory of neurological ailments [51]. Clinical studies have also shown a relationship between NSE concentrations and the severity of PHN [52]. As NSE levels taper off, both the condition and pain-related symptoms markedly improve. This finding mirrors the strong association between NSE concentrations and short-term outcomes in patients with PHN, with both high sensitivity and specificity as an indicator for PHN. Myelin basic protein (MBP), which is fundamental to myelin sheaths, not only boosts signal propagation but also operates as a potential autoantigen. It can stimulate T cells, playing a vital role in diseases characterized by myelin sheath deterioration [53]. Investigations into the relationship between circulating MBP concentrations and PHN have revealed that patients diagnosed with PHN often exhibit increased MBP levels during the early stages of HZ relative to those who do not develop PHN [54]. These findings suggest that MBP might be involved in the pathogenesis of PHN and could function as a prognostic marker. An increase in plasma galectin-3 concentrations has been noted in patients with breast cancer receiving paclitaxel for chemotherapy-induced peripheral neuropathy (CIPN), as well as in murine models of paclitaxel-triggered CIPN. A retrospective examination revealed a notable increase in the serum galectin-3 concentration in patients with HZ-associated early neuralgia (HZ-EN) and patients with PHN, revealing a positive relationship with pain intensity. These findings suggest that galectin-3 could play a part in the onset and progression of HZ-EN and PHN [55]. For instance, the presence of the blood‒brain barrier complicates the identification of nerve injury-associated proteins that seep into the bloodstream in minuscule amounts. Moreover, serum biomarkers generally exhibit a temporal lag following nerve injury. Challenges notwithstanding, serum analysis remains a feasible, readily accessible, and ultrasensitive modality for assessing the severity and progression of nerve trauma, thereby offering predictive insights into the likelihood of developing PHN.

Genetics

There is significant research focusing on the genotype of genes related to PHN, with human leukocyte antigen (HLA) as the primary point of interest. Initial Japanese studies revealed strong relationships between the HLA-I antigens A33 and B44 and PHN in the local population. Research has highlighted significant associations between the HLA-A3303, HLA-B4403, and HLA-DRB11302 alleles and PHN [56, 57]. In Korea, different HLA alleles were identified in patients with PHN than in healthy individuals, with a notable increase in the frequency of HLA-B44 in patients with PHN when compared with that in patients with HZ [58]. Notably, the affinity of VZV peptides for these HLA variants differed, with HLA-A02 showing a much greater affinity for VZV peptides than HLA-B44 [59]. HLA gene variants seem to be intertwined with the pathogenesis of PHN, although most related research is region-centric.

Disturbances in energy metabolism can affect nerve cell functionality and repair capabilities, which can accelerate the emergence of neuropathic pain. A particular study revealed noticeable differences in the genotype distribution and allele frequencies of the rs3783641 single-nucleotide polymorphism (SNP) in the GCH1 gene among the groups [60]. Research has identified correlations between AMPK gene (PRKAA1) polymorphisms and PHN [61]. Inflammation, neural signaling, and neurodevelopment-related pathways are critical in neuropathic pain research. One study analyzed 24 candidate genetic polymorphisms from 12 genes and revealed that only the variation in the P2X purinoceptor 7 (P2RX7) gene was associated with increased PHN susceptibility [62]. Another study using a GWAS revealed a significant association between the rs4773840 SNP in the ABCC4 gene and PHN [63]. These findings underscore the immense potential of genotypes as biomarkers for predicting PHN.

PHN is a multifaceted disease influenced by various genes and environmental factors. Current genetic tests analyze only specific genes, and other influential factors may impede accurate predictions. Only a handful of gene variations associated with PHN are known at present, and the accuracy of predictions based on these sequences may be less than ideal. Therefore, while genetic testing offers substantial potential, additional research is needed to confirm its reliability and broader application.

Proteomics and Metabolomics

In the specific context of PHN research, proteomics and metabolomics offer complementary insights. A remarkable study revealed crucial insights. Elevated expression of the S100A9 protein in the dorsal root ganglia following VZV infection was observed, hinting at its potential role in triggering acute inflammatory responses [64]. Furthermore, in patients with HZ, there was a notable increase in the expression of proteins linked to cell structure and epithelial tissue damage, leading to an increase in inflammatory agents. Another study showed that the glucose-alanine cycle, tryptophan metabolism, tyrosine metabolism, lactose degradation, and malate–aspartate shuttle are the five major metabolic pathways involved in PHN evolution using pathway analysis [65]. The combined biomarker model accurately predicts PHN. In PHN sufferers, disturbances in fatty acid metabolites combined with heightened inflammatory triggers seemed to negatively impact serotonin metabolism, compromising inhibitory systems and amplifying neural sensitivity. The high accuracy of the metabolomics analysis indicates the potential for predicting HZ-induced PHN. It can also be used to understand the pathogenesis and metabolic pathways of diseases. This study has certain limitations. Metabolites are sensitive to many factors, and additional key metabolites may be found in multicenter, large-sample prospective studies.

Epidermal Nerve Fibers

Damage to nerve endings and nerve fibers caused by viral infection and inflammation, as well as abnormal repair, might be significant causes of acute HZ neuralgia and PHN. Therefore, epidermal nerve fiber testing may be a useful tool and potential biomarker in future research in patients with PHN.

Quantification of Small Nerve Fibers

An analysis comparing intraepidermal nerve fiber density (IENFD) between patients with PHN and PHN-free controls highlighted a significant association between a pronounced reduction in cutaneous sensory nerve endings and the occurrence of PHN following an HZ outbreak [66]. Furthermore, a controlled investigation discerned a correlation between intraepidermal nerve innervation density and the onset of PHN, noting a markedly increased nerve fiber density in patients without PHN [67]. When comparing affected and unaffected skin areas in patients with PHN, a stark reduction in IENFD was evident on the affected side [68]. Given the parallels in the transmission pathways of itch and pain, experts postulate an intrinsic connection between pruritus and pain etiologies [69]. Remarkably, as one patient’s pruritus symptoms receded, subsequent skin biopsies indicated a restoration of nerve fiber density to typical levels [70]. It is possible that PHN is a neurological anomaly tied to the depletion of nociceptors. Avoiding PHN might hinge on retaining a baseline density of primary nociceptor neurons. Consequently, epidermal innervation density could act as an indicator for predicting the likelihood of PHN pain.

Functionality of Small Nerve Fibers

Assessing IENFD in skin samples from patients with PHN, researchers identified an inverse relationship between atypical pain severity and the extent of decline in skin nerve innervation [68]. In contrast, direct assessments of C-fiber function indicate a direct link between pain and irregular pain severity [71]. This apparent disparity arises from the different metrics used to gauge peripheral nerve quantity versus function. Diminished C-fibers do not always equate to a reduction in IENFD. Pain accompanied by sensory dysfunction typically signifies a less favorable prognosis, whereas patients devoid of sensory anomalies often exhibit improved medication responsiveness [72]. Further subdivisions based on patients’ sensory profiles revealed marked variations in pain duration across groups [73]. In subjects who experienced PHN for less than 1 year, persistent pain intensity was directly correlated with dynamic mechanical stimulation-related abnormal pain intensity. This relationship was not found in patients with persistent PHN for more than a year [74]. Assessing small-fiber nerve function could pave the way for superior biological markers, differentiating PHN patient clusters and progression phases.

Notably, pathological vibration sensations in patients’ lower extremities predicted PHN with an impressive 70% sensitivity. However, the functions of nociceptive C fibers and parasympathetic fibers are consistent between patients with and without PHN [75]. These findings suggest that preexisting large-fiber conduction anomalies, particularly those linked with latent polyneuropathy, play a crucial role in PHN progression. Further studies have shown that individuals exhibiting both mechanical hypoesthesia and hyperalgesia/abnormal pain during acute herpetic zoster (AHZ) eventually develop PHN [76, 77]. Intriguingly, reduced thermal sensation during AHZ seems to serve as a protective mechanism against PHN [78]. Thermal hyperalgesia, a chief symptom of peripheral sensitization, along with distant body part hyposensitivity and hyperalgesia, might directly correlate with the neural pathways spanning the spinal cord. Inflammation within the central nervous system, coupled with the severity of nerve damage during AHZ, appears to profoundly influence the development of PHN. With advancements in medical sciences leading to noninvasive, efficient, and automated testing, these issues are expected to be reduced. Furthermore, quantitative analyses of small nerve fibers can provide accurate, quick, and user-friendly data for PHN prediction.

Magnetic Resonance Imaging

The transition from acute HZ to PHN is characterized by significant alterations in both the structure and function of the brain (Fig. 3). Research has shown that there is a loss of volume in gray matter (GM) regions accompanied by functional shifts in the insula, brainstem, and frontal lobe in both patients with HZ and PHN. Intriguingly, these patients can display varied brain changes in areas such as the cerebellar tonsil, central anterior gyrus, and temporal, occipital, and parietal lobes, potentially highlighting risk factors for PHN development [79]. Notably, in contrast to their HZ counterparts, patients with PHN have decreased GM volume in regions such as the left hippocampal gyrus, nucleus accumbens, and precentral gyrus but an increase in the right pulvinar [80]. In a side-by-side comparison of patients with PHN and HZ, irregularities in areas such as the left cerebellar tonsil, corpus callosum, and left lentiform nucleus emerged as potential precursors to the HZ–PHN transition [81]. Compared with patients with HZ, patients with PHN typically exhibit reduced thicknesses in the left insular and frontal opercular cortex (LFOP4) and the left motor cortex (L3B). These reductions in LFOP4 and L3B may be pivotal in signifying the transition from HZ to PHN, as the thickness of these areas is inversely related to the duration of both HZ and PHN [82].Fig. 3 The application of magnetic resonance in predicting postherpetic neuralgia. BGN basal ganglia network, DMN default mode network, DTI diffusion tensor imaging, ERN emotion regulation network, fMRI functional magnetic resonance imaging, GM gray matter, L3B left motor cortex, LFOP4 left insular and frontal opercular cortex, PAG periaqueductal gray matter, RVM rostral ventromedial medulla, SN salience network

Huang’s group pioneered the creation of classification models with high sensitivity and specificity by investigating intrinsic brain activity and employing fMRI-based categorization in patients with HZ and PHN [83]. From a broader perspective, the progression from HZ to PHN triggered considerable fluctuations in localized brain activity in pain-associated regions, such as the frontal lobe, thalamus, cerebellum, brainstem, limbic system, and temporal lobes [84]. These functional modifications might facilitate the progression from HZ to PHN, potentially causing persistent chronic pain in patients with PHN. As HZ progresses to PHN, there is a significant surge in neural activity within broad regions of the cerebellum and a notable decrease in the occipital, temporal, parietal, and limbic lobes [85]. These changes, evaluated by fMRI, provide vital insights for predicting PHN onset.

An investigation of diffusion tensor imaging (DTI) data from patients with HZ and PHN revealed light anomalies in the diffusion patterns of white matter fibers in patients with PHN [86]. This diffusion irregularity suggests alterations in the microstructure of the white matter, potentially jeopardizing communication between relevant brain sections and influencing the broader neural re-encoding linked to PHN. In comparison, patients with PHN exhibited more pronounced microstructural distortions in zones associated with HZ-PHN evolution than did patients with HZ. An illustrative study encompassing five patients with HZ revealed an increase in functional connectivity between the left superior frontal gyrus (SFG) and right inferior frontal gyrus (IFG) in patients progressing to PHN [87]. Variations in brain region activation might be pivotal markers and underlying mechanisms for PHN onset.

Resting-state fMRI scans have identified inconsistencies in the neural connections between networks such as the default mode network (DMN), salience network (SN), emotion regulation network (ERN), and basal ganglia network (BGN) in patients with PHN and HZ relative to healthy controls. Notably, abnormalities in the DMN-BGN and internal BGN connections were also prevalent among patients with PHN [88]. While the pain intensity in patients with HZ correlated positively with network activity, patients with PHN did not show a marked increase in network connectivity [89]. This divergence necessitates further exploration into the kinds of abnormalities that could presage the onset of PHN. Given its indirect method of gauging neural activity through changes in brain oxygen levels, fMRI navigates complex physical and physiological terrains. This means that fMRI is not always unequivocal in interpreting brain activity, nor can it achieve precise single-neuron measurements. Additionally, the necessity for baseline imaging before capturing any response extends its duration. The steep financial requisites for fMRI equipment and expertise further limit its accessibility.

Other Biomarkers

Electromyography (EMG) serves as a diagnostic technique for gauging electrical activity within muscles, predominantly aiding in identifying muscle and nerve dysfunctions. A study examining EMG data in 91 patients revealed that compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes in the afflicted limb’s median nerve were autonomous factors influencing PHN [13]. These amplitudes demonstrated robust predictive ability for PHN. However, despite its diagnostic and therapeutic significance in neuropathic pain, EMG has inherent limitations. Specifically, while EMG easily examines and quantifies muscle and nerve electrical activity, it cannot directly measure pain intensity. Its application also mandates specialized equipment and trained practitioners, potentially constraining its accessibility due to varying costs and availability in certain areas.

Infrared thermography has potential for providing valuable data regarding the site and intensity of neuropathic pain. A study revealed that a heightened temperature disparity between the two sides significantly increased the incidence of PHN [90]. However, due to variations in inclusion benchmarks and participant numbers, some research contends that infrared thermography does not possess robust predictive power for PHN onset [91]. To efficiently utilize this technique, there is a need for technical support, dedicated equipment, and the knowledge of experienced medical professionals for accurate interpretation. Depending solely on this method might not capture the full spectrum of pain-related information, underlining the importance of combining this method with other medical documentation and physical assessments.

Conclusion and Future Perspectives

Biomarkers rooted in tangible clinical evaluations aligned with disease genesis provide a benchmark for disease risk assessment (Fig. 4). Alterations in blood components, such as cytokines and specific immune cells, indicate inflammation levels and the state of immunosuppression during acute phases, with proven predictive power for PHN. Molecular shifts linked to nerve damage indicate the scale of injury and can anticipate subsequent complications. Variability in gene expression can segregate high-risk and low-risk factions. Advances in proteomics and metabolomics can help researchers delve into protein interactions or detect irregularities in bodily metabolites, opening doors to tailored risk predictions and potentially revealing more potent biomarkers. Diagnostic methods such as neuropathy detection and EMG provide personalized insights, providing a roadmap for preventing PHN and initiating early treatments (Table 1). However, as enlightening as biomarker studies are, constraints such as exorbitant costs, limited study samples, and unrepresentative cohorts might hinder their reach.Fig. 4 Potential biomarkers for postherpetic neuralgia: a laboratory test overview. IL interleukin, NK natural killer, NLR neutrophil-to-lymphocyte ratio, PHN postherpetic neuralgia, VZV varicella-zoster virus

Table 1 Potential biomarkers for postherpetic neuralgia: an examination overview

Biomarker	Sample	Grouping	Results	Study	
IENFD	Skin	n = 18 (PHN) painful skin areas and compared with normal contralateral skin	Allodynia severity correlated with nerve fiber loss in PHN skin (Kendall τ = 0.40, P = 0.02)

Spontaneous PHN pain correlated with nerve fiber loss in PHN skin (Kendall τ = −0.20, P = 0.24)

Pain intensity correlated with nerve fiber loss in PHN skin (Kendall τ = −0.46, P 5 0.06)

	[68]	
	Skin	n = 34 HZ developed PHN (n = 18) HZ not developed PHN (n = 16)	Correlation between the presence or absence of PHN pain and neurites at the shingles-affected sites: densities of epidermal neurites (r = −0.66, P 5 0.001)

Densities of dermal neurites (r = −0.69, P 5 0.001)

	[66]	
	Skin	n = 38 HZ developed PHN (n = 19) HZ not developed PHN (n = 19)	Of 19 subjects without PHN, 17 had more than 670 neurites/mm2 skin surface area (mean ± SEM = 1569 ± 230)

Of 19 subjects with PHN, 18 had 640 or fewer neurites/mm2 (mean ± SEM = 367 ± 92)

	[67]	
Functionality of small nerve fibers	Skin	n = 34 HZ developed PHN (n = 17) HZ not developed PHN (n = 17)	The difference in quantitative vibrometry thresholds at the lower extremity was statistically significant (U-test, P = 0.0241)

The stochastic dependency of vibration sense and development of PHN was statistically significant (P, 0.05, chi-square test)

	[75]	
	Skin	n = 58 HZ developed PHN (n = 17) HZ not developed PHN (n = 45)	The presence of DMA (P = 0.010, Fisher Test) and an impaired vibration detection thresholds (VDT-loss P = 0.036, Fisher test) at the control more frequent

Patients without PHN indeed showed a sensory deficit of thermal detection, i.e. 31.1% (n = 14; P = 0.025) at the affected site and 13.3% (n = 6; P > 0.05) at the control site

	[78]	
GM volume	MRI	n = 83 HZ (n = 33) PHN (n = 22) matching healthy volunteers (n = 28)	The AUC values in bilateral insula (AUC = 0.938 for right insula and 0.890 for left insula), bilateral precentral gyrus (AUC = 0.821 for right precentral gyrus and 0.835 for left precentral gyrus), right MFG (AUC = 0.885), and left postcentral gyrus (AUC = 0.881) were relatively high, which showed reliable classification to discriminate patients with PHN from HCs	[81]	
	MRI	n = 72 HZ (n = 28) PHN (n = 24) healthy controls (n = 20)	Significant correlation between the mean ALFF and PRI in the PHN group, but not in the HZ group (PHN: r = −0.535, P = 0.015; HZ: r = −0.343, P = 0.101)

For HZ and PHN classification, the use of ALFF in the same ROI achieved a classification accuracy of 61.54% (sensitivity 60.71%, specificity 62.5%, P < 0.081)

	[83]	
	MRI	n = 74 HZ (n = 25) PHN (n = 28) healthy controls (n = 21)	The GM volume of the right putamen was positively correlated with illness duration in patients with PHN (r = 0.379, P = 0.047)	[80]	
	MRI	n = 89 HZ (n = 29) PHN (n = 30) matching healthy controls (n = 30)	Negative correlation linking the thickness values of the LFOP4 (r = −0.28, P = 0.033) and left motor cortex L3B (r = −0.2, P = 0.027) to the duration of disease in patients with HZ and PHN	[82]	
fMRI	MRI	n = 128 HZ (n = 50) PHN (n = 23) healthy controls (n = 55)	Compared with HZ, PHN brain showed significantly increased ReHo and fALFF mainly in most of the cerebellum. Lower ReHo and fALFF values were observed in the limbic system, temporal lobe, occipital lobe, and parietal lobe	[85]	
	MRI	12 patients with a transition from HZ to PHN	PHN brain showed significantly increased ReHo mainly in the bilateral cerebellum and the middle frontal gyrus. Lower ReHo values in the right sub-lobar area and the bilateral limbic lobe	[84]	
DTI	MRI	n = 116 HZ (n = 48) PHN (n = 40) matching healthy controls (n = 28)	Compared with those in the HZ group, the mean dispersion coefficient (MD), radial dispersion coefficient (RD), and axial dispersion coefficient (AD) values were significantly increased (P < 0.01, TFCE correction) in some brain regions of the PHN group	[86]	
	MRI	n = 98 HZ (n = 33) PHN (n = 31) healthy controls (n = 34)	Different levels of within-BGN connectivity accompanied by different emotional and ruminative states

The difference in NAc-mPFC (key nodes of DMN and BGN, respectively) connectivity may account for the chronic pain transition mechanism

	[88]	
	MRI	Five patients with HZ, three developed PHN	In the subjects with PHN, the FC of the left superior frontal gyrus (SFG) and the right inferior frontal gyrus (IFG) were activated	[87]	
	MRI	n = 150 HZ (n = 50) PHN (n = 50) healthy controls (n = 50)	Compared with PHN, patients with HZ exhibited higher global network efficiency, together with greater functional connectivity between the vFC in CON and occipital cortex in ON, which was associated with pain intensity and this connectivity may effectively distinguish HZ and patients with PHN (specificity = 83.33%)	[89]	
EMG	EMG	n = 91 mild HZ (n = 29) moderate HZ (n = 31) severe HZ (n = 31)	CMAP and SNAP amplitudes of the median nerve on the affected limb had a high predictive value for PHN (AUC = 0.657, P = 0.010; AUC = 0.773, P < 0.001)

The cutoff values were 5.45 mV and 10.80 mV, respectively; and the predictive value of the two indices combined was the highest (AUC = 0.785, P < 0.001)

	[13]	
Infrared thermography	Infrared thermography	n = 112 (HZ) HZ developed PHN (n = 35)	Statistically significant difference between the two groups (△T 1.2 °C vs. 0.6 °C, P = 0.028)

Development of PHN was associated with △T > 0.5 (P = 0.029)

	[90]	
AD axial dispersion coefficient, ALFF amplitude of low-frequency fluctuation, AUC area under the curve, BGN basal ganglia network, CMAP compound muscle action potential, CON cingulo-opercular network, DMA dynamic muscle activation, DMN default mode network, DTI diffusion tensor imaging, EMG electromyography, fALFF fractional amplitude of low frequency fluctuations, FCD functional connectivity density, fMRI functional magnetic resonance imaging, GM gray matter, HCs healthy controls, HZ herpes zoster, IENFD intraepidermal nerve fiber density, IFG inferior frontal gyrus, L3B left motor cortex, LFOP4 left insular and frontal opercular cortex, MD mean dispersion, MFG middle frontal gyrus, MRI magnetic resonance imaging, NAc-mPFC nucleus accumbens-medial prefrontal cortex, ON olfactory nerve, PHN postherpetic neuralgia, PRI pain rating index, RD radial dispersion, ReHo regional homogeneity, ROI region of interest, SFG superior frontal gyrus, SEM standard error of the mean, SNAP sensory nerve action potential, TFCE threshold-free cluster enhancement, VDT vibration detection thresholds, vFC ventral frontal cortex

The combination of both risk factors and biomarkers represents a holistic and precise health and disease risk assessment approach. Biomarkers, as early warning systems, can flag potential disease markers. By examining these markers in biological samples, disease presence or predisposition becomes discernible, facilitating presymptomatic predictions. This knowledge, when combined with risk factor data, refines an individual’s disease risk evaluation. Tailoring treatment blueprints and preventive steps to resonate with a person’s risk factors and biomarkers not only heightens treatment success but also mitigates unwanted repercussions. Similar to intricate neurological ailments such as Alzheimer’s disease, a solitary biomarker is unlikely to be a definitive predictor for PHN. However, when modern analytical tools, such as neural networks, artificial intelligence, or machine learning algorithms, are used to create a composite PHN biomarker profile, there is a strong chance of revealing the mysteries of PHN and developing innovative treatments.

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. This review advances the understanding of postherpetic neuralgia (PHN) by summarizing current research on biological markers, thereby laying the groundwork for future studies in an under-researched field. It underscores the necessity of multicenter pilot studies to identify specific, sensitive biomarkers that could improve disease diagnosis and management. Despite the potential selection bias due to search methodologies on PubMed that may overlook less common techniques or specifically focused studies, it elucidates the clinical significance of such markers in early disease detection. However, accessibility and affordability of appropriate diagnostic tests pose a challenge, given the current lack of highly sensitive markers and the prohibitive cost of more comprehensive methods like functional MRI.

Research to date is mainly single-center and may not be representative, suffering from methodological limitations such as inclusivity of only late-stage patients and a paucity of baseline data. Additionally, patient heterogeneity across studies reflects a lack of generalizable findings. Despite these challenges, some correlations have emerged, guiding the choice of detection methods and informing protocol designs for future research. From a cost-effectiveness perspective, the review suggests tiered screening strategies, prioritizing simple, cost-effective tests for broader populations and reserving more expensive, invasive procedures for those at greatest risk. Such an approach not only prevents unnecessary diagnostic resource expenditure but also mitigates the possibility of post-disease complications, thereby reducing overall social and medical care costs.

Promptly administering antiviral therapy and ensuring its full course can markedly reduce the risk of PHN, with those at increased risk receiving the greatest benefit [92, 93]. Implementing immediate pain management, in tandem with mood stabilization and sleep induction, has led to a significant decline in patients with PHN, especially in high-risk populations. In addition to drug-based interventions, more invasive treatments, such as local tissue procedures, nerve root interventions, and pulsed radio frequency, are recommended for those at elevated risk, as they can reduce complication rates [94, 95]. Traditional Chinese medicine such as acupuncture has shown potential for treating pain in certain areas, although additional extensive studies are needed [96]. In the aftermath of PHN, it is vital to deploy robust measures to counter sleep disturbances and emotional irregularities stemming from persistent pain, as these can exacerbate pain duration [97, 98]. Biological markers play a pivotal role in gauging the success of treatments and how individuals respond. Periodic assessment of these markers can track the trajectory and impact of treatments, allowing for timely alterations to therapeutic regimens.

Current research endeavors focused on PHN predominantly involve the collection of patient blood, tumor samples, and microbiome data. Research has focused on assimilating genomic information (mutations or methylation) and immune functionalities (T-cell activity) from easily obtainable sources such as blood, fecal matter, and urine to explore elements that drive the onset and progression of PHN. Considering the pressing medical demand for more forward-looking PHN investigations, collating and dissecting biomarker data could offer a valuable foundation for clinical application.

Author Contributions

Yunze Li wrote the main manuscript text and prepared the figures. Zhiying Feng and Xianhui Kang guided and revised the article. Jiali Jin summarized the article’s content. All authors reviewed the manuscript.

Funding

This work was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (No. LQ22H090022 to Yunze Li), the National Natural Science Foundation of China (No. 82271239 to Zhiying Feng) and the Key R&D Program of Zhejiang (No. 2022C03081 to Zhiying Feng). The journal’s Rapid Service Fee was funded by the authors.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Conflict of Interest

Yunze Li, Jiali Jin, Xianhui Kang and Zhiying Feng have nothing to disclose.

Ethical Approval

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
==== Refs
References

1. van Oorschot D Vroling H Bunge E Diaz-Decaro J Curran D Yawn B A systematic literature review of herpes zoster incidence worldwide Hum Vaccin Immunother 2021 17 1714 1732 33651654
van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17:1714–32.33651654
2. Liu X Wei L Zeng Q Lin K Zhang J The treatment of topical drugs for postherpetic neuralgia: a network meta-analysis Pain Physician 2020 23 541 551 33185370
Liu X, Wei L, Zeng Q, Lin K, Zhang J. The treatment of topical drugs for postherpetic neuralgia: a network meta-analysis. Pain Physician. 2020;23:541–51.33185370
3. Johnson RW Rice AS Clinical practice. Postherpetic neuralgia N Engl J Med 2014 371 1526 1533 25317872
Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371:1526–33.25317872
4. Chen L Li J Liu H Yang P Zuo Y Ye L Interventions for zoster-associated pain: a retrospective study based on the clinical database Front Neurol 2022 13 1056171 36504661
Chen L, Li J, Liu H, Yang P, Zuo Y, Ye L. Interventions for zoster-associated pain: a retrospective study based on the clinical database. Front Neurol. 2022;13:1056171.36504661
5. Oskay T Keskin C Özen M Antioxidant and inflammatory biomarkers in herpes zoster J Med Virol 2022 94 3924 3929 35426146
Oskay T, Keskin C, Özen M. Antioxidant and inflammatory biomarkers in herpes zoster. J Med Virol. 2022;94:3924–9.35426146
6. Peng Q Guo X Luo Y Wang G Zhong L Zhu J Li Y Zeng X Feng Z Dynamic immune landscape and VZV-specific T cell responses in patients with herpes zoster and postherpetic neuralgia Front Immunol 2022 13 887892 35720399
Peng Q, Guo X, Luo Y, Wang G, Zhong L, Zhu J, Li Y, Zeng X, Feng Z. Dynamic immune landscape and VZV-specific T cell responses in patients with herpes zoster and postherpetic neuralgia. Front Immunol. 2022;13: 887892.35720399
7. Schmader K Herpes zoster Ann Intern Med 2018 169 Itc19 itc31 30083718
Schmader K. Herpes zoster. Ann Intern Med. 2018;169:Itc19-itc31.30083718
8. Buchan SA Daneman N Wang J Wilson SE Garber G Wormsbecker AE Antoniou T Deeks SL Herpes zoster in older adults in Ontario, 2002–2016: investigating incidence and exploring equity PLoS ONE 2021 16 e0246086 33571224
Buchan SA, Daneman N, Wang J, Wilson SE, Garber G, Wormsbecker AE, Antoniou T, Deeks SL. Herpes zoster in older adults in Ontario, 2002–2016: investigating incidence and exploring equity. PLoS ONE. 2021;16: e0246086.33571224
9. Cho SI Lee DH Park YM Identification of herpes zoster high-risk group using Charlson comorbidity index: a nationwide retrospective cohort study J Dermatol 2020 47 47 53 31642113
Cho SI, Lee DH, Park YM. Identification of herpes zoster high-risk group using Charlson comorbidity index: a nationwide retrospective cohort study. J Dermatol. 2020;47:47–53.31642113
10. Imafuku S Dormal G Goto Y Jégou C Rosillon D Matsuki T Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014 J Dermatol 2020 47 236 244 31953880
Imafuku S, Dormal G, Goto Y, Jégou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: results from a claims database cohort study, from 2005 to 2014. J Dermatol. 2020;47:236–44.31953880
11. Xing X Sun K Yan M Delayed initiation of supplemental pain management is associated with postherpetic neuralgia: a retrospective study Pain Physician 2020 23 65 72 32013280
Xing X, Sun K, Yan M. Delayed initiation of supplemental pain management is associated with postherpetic neuralgia: a retrospective study. Pain Physician. 2020;23:65–72.32013280
12. Du J Sun G Ma H Xiang P Guo Y Deng Y Li S Li X Prevalence and risk factors of anxiety and depression in patients with postherpetic neuralgia: a retrospective study Dermatology 2021 237 891 895 33326962
Du J, Sun G, Ma H, Xiang P, Guo Y, Deng Y, Li S, Li X. Prevalence and risk factors of anxiety and depression in patients with postherpetic neuralgia: a retrospective study. Dermatology. 2021;237:891–5.33326962
13. Tang J Luo G Tao J Zhu J He Q Ni H Xie K Xu L Yao M Correlation between electromyography and severity and prognosis of upper limb herpes zoster Pain Physician 2022 25 E749 e757 35901486
Tang J, Luo G, Tao J, Zhu J, He Q, Ni H, Xie K, Xu L, Yao M. Correlation between electromyography and severity and prognosis of upper limb herpes zoster. Pain Physician. 2022;25:E749-e757.35901486
14. Li T Wang J Xie H Hao P Qing C Zhang Y Liao X Liang T Study on the related factors of post-herpetic neuralgia in hospitalized patients with herpes zoster in Sichuan Hospital of Traditional Chinese Medicine based on big data analysis Dermatol Ther 2020 33 e14410 33052606
Li T, Wang J, Xie H, Hao P, Qing C, Zhang Y, Liao X, Liang T. Study on the related factors of post-herpetic neuralgia in hospitalized patients with herpes zoster in Sichuan Hospital of Traditional Chinese Medicine based on big data analysis. Dermatol Ther. 2020;33: e14410.33052606
15. Wang XX Zhang Y Fan BF Predicting postherpetic neuralgia in patients with herpes zoster by machine learning: a retrospective study Pain Ther 2020 9 627 635 32915399
Wang XX, Zhang Y, Fan BF. Predicting postherpetic neuralgia in patients with herpes zoster by machine learning: a retrospective study. Pain Ther. 2020;9:627–35.32915399
16. Zhang J Ding Q Li XL Hao YW Yang Y Support vector machine versus multiple logistic regression for prediction of postherpetic neuralgia in outpatients with herpes zoster Pain Physician 2022 25 E481 e488 35652777
Zhang J, Ding Q, Li XL, Hao YW, Yang Y. Support vector machine versus multiple logistic regression for prediction of postherpetic neuralgia in outpatients with herpes zoster. Pain Physician. 2022;25:E481-e488.35652777
17. Peng Z Guo J Zhang Y Guo X Huang W Li Y Yan Z Guo N Ke D Chen L Huang J Feng Z Development of a model for predicting the effectiveness of pulsed radiofrequency on zoster-associated pain Pain Ther 2022 11 253 267 35094299
Peng Z, Guo J, Zhang Y, Guo X, Huang W, Li Y, Yan Z, Guo N, Ke D, Chen L, Huang J, Feng Z. Development of a model for predicting the effectiveness of pulsed radiofrequency on zoster-associated pain. Pain Ther. 2022;11:253–67.35094299
18. Forbes HJ Thomas SL Smeeth L Clayton T Farmer R Bhaskaran K Langan SM A systematic review and meta-analysis of risk factors for postherpetic neuralgia Pain 2016 157 30 54 26218719
Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, Langan SM. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157:30–54.26218719
19. Gershon AA Breuer J Cohen JI Cohrs RJ Gershon MD Gilden D Grose C Hambleton S Kennedy PG Oxman MN Seward JF Yamanishi K Varicella zoster virus infection Nat Rev Dis Primers 2015 1 15016 27188665
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, Seward JF, Yamanishi K. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.27188665
20. Gerada C Campbell TM Kennedy JJ McSharry BP Steain M Slobedman B Abendroth A Manipulation of the innate immune response by varicella zoster virus Front Immunol 2020 11 1 32038653
Gerada C, Campbell TM, Kennedy JJ, McSharry BP, Steain M, Slobedman B, Abendroth A. Manipulation of the innate immune response by varicella zoster virus. Front Immunol. 2020;11:1.32038653
21. Mok CC Ho LY Tse SM Chan KL To CH Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies Clin Rheumatol 2023 42 1019 1026 36385600
Mok CC, Ho LY, Tse SM, Chan KL, To CH. Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies. Clin Rheumatol. 2023;42:1019–26.36385600
22. Sim JH Moon YJ Kim SH Kim KS Lee JS Song JG Hwang GS Association between neutrophil-lymphocyte ratio and herpes zoster infection in 1688 living donor liver transplantation recipients at a large single center Biomedicines 2021 9 963 34440167
Sim JH, Moon YJ, Kim SH, Kim KS, Lee JS, Song JG, Hwang GS. Association between neutrophil-lymphocyte ratio and herpes zoster infection in 1688 living donor liver transplantation recipients at a large single center. Biomedicines. 2021;9:963.34440167
23. Zhang Y Jiang L Yang P Zhang Y Comparison of lymphocyte count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting the severity and the clinical outcomes of acute cerebral infarction patients Clin Lab 2019 10.7754/clin.lab.2019.190102 31854959
Zhang Y, Jiang L, Yang P, Zhang Y. Comparison of lymphocyte count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting the severity and the clinical outcomes of acute cerebral infarction patients. Clin Lab. 2019. 10.7754/clin.lab.2019.190102.31854959 10.7754/clin.lab.2019.190102
24. Bowers NL Helton ES Huijbregts RP Goepfert PA Heath SL Hel Z Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway PLoS Pathog 2014 10 e1003993 24626392
Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 2014;10: e1003993.24626392
25. Diez-Domingo J Parikh R Bhavsar AB Cisneros E McCormick N Lecrenier N Can COVID-19 increase the risk of herpes zoster? A narrative review Dermatol Ther (Heidelb) 2021 11 1119 1126 33999370
Diez-Domingo J, Parikh R, Bhavsar AB, Cisneros E, McCormick N, Lecrenier N. Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb). 2021;11:1119–26.33999370
26. Wei L Zhao J Wu W Zhang Y Fu X Chen L Wang X Decreased absolute numbers of CD3(+) T cells and CD8(+) T cells during aging in herpes zoster patients Sci Rep 2017 7 15039 29118328
Wei L, Zhao J, Wu W, Zhang Y, Fu X, Chen L, Wang X. Decreased absolute numbers of CD3(+) T cells and CD8(+) T cells during aging in herpes zoster patients. Sci Rep. 2017;7:15039.29118328
27. Chen W Zhu L Shen LL Si SY Liu JL T lymphocyte subsets profile and toll-like receptors responses in patients with herpes zoster J Pain Res 2023 16 1581 1594 37220634
Chen W, Zhu L, Shen LL, Si SY, Liu JL. T lymphocyte subsets profile and toll-like receptors responses in patients with herpes zoster. J Pain Res. 2023;16:1581–94.37220634
28. Xing Q Hu D Shi F Chen F Role of regulatory T cells in patients with acute herpes zoster and relationship to postherpetic neuralgia Arch Dermatol Res 2013 305 715 722 23689682
Xing Q, Hu D, Shi F, Chen F. Role of regulatory T cells in patients with acute herpes zoster and relationship to postherpetic neuralgia. Arch Dermatol Res. 2013;305:715–22.23689682
29. Le P Rothberg M Herpes zoster infection BMJ 2019 364 k5095 30630827
Le P, Rothberg M. Herpes zoster infection. BMJ. 2019;364: k5095.30630827
30. Laing KJ Ouwendijk WJD Campbell VL McClurkan CL Mortazavi S Elder Waters M Krist MP Tu R Nguyen N Basu K Miao C Schmid DS Johnston C Verjans G Koelle DM Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster Nat Commun 2022 13 6957 36376285
Laing KJ, Ouwendijk WJD, Campbell VL, McClurkan CL, Mortazavi S, Elder Waters M, Krist MP, Tu R, Nguyen N, Basu K, Miao C, Schmid DS, Johnston C, Verjans G, Koelle DM. Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster. Nat Commun. 2022;13:6957.36376285
31. Sutherland JP Steain M Buckland ME Rodriguez M Cunningham AL Slobedman B Abendroth A Persistence of a T cell infiltrate in human ganglia years after herpes zoster and during post-herpetic neuralgia Front Microbiol 2019 10 2117 31572325
Sutherland JP, Steain M, Buckland ME, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A. Persistence of a T cell infiltrate in human ganglia years after herpes zoster and during post-herpetic neuralgia. Front Microbiol. 2019;10:2117.31572325
32. Park SY Kim JY Kwon JS Jeon NY Kim MC Chong YP Lee SO Choi SH Kim YS Woo JH Kim SH Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster J Med Virol 2019 91 1995 2000 31286531
Park SY, Kim JY, Kwon JS, Jeon NY, Kim MC, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster. J Med Virol. 2019;91:1995–2000.31286531
33. Weinberg A Canniff J Rouphael N Mehta A Mulligan M Whitaker JA Levin MJ Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults J Immunol 2017 199 604 612 28607114
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, Levin MJ. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12.28607114
34. Vukmanovic-Stejic M Sandhu D Seidel JA Patel N Sobande TO Agius E Jackson SE Fuentes-Duculan J Suárez-Fariñas M Mabbott NA Lacy KE Ogg G Nestle FO Krueger JG Rustin MHA Akbar AN The characterization of varicella zoster virus-specific T cells in skin and blood during aging J Invest Dermatol 2015 135 1752 1762 25734814
Vukmanovic-Stejic M, Sandhu D, Seidel JA, Patel N, Sobande TO, Agius E, Jackson SE, Fuentes-Duculan J, Suárez-Fariñas M, Mabbott NA, Lacy KE, Ogg G, Nestle FO, Krueger JG, Rustin MHA, Akbar AN. The characterization of varicella zoster virus-specific T cells in skin and blood during aging. J Invest Dermatol. 2015;135:1752–62.25734814
35. Fernández-Ruiz M Origüen J Lora D López-Medrano F González E Polanco N San Juan R Ruiz-Merlo T Parra P Andrés A Aguado JM Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study Transpl Int 2018 31 187 197 28940695
Fernández-Ruiz M, Origüen J, Lora D, López-Medrano F, González E, Polanco N, San Juan R, Ruiz-Merlo T, Parra P, Andrés A, Aguado JM. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study. Transpl Int. 2018;31:187–97.28940695
36. Morrow G Slobedman B Cunningham AL Abendroth A Varicella-zoster virus productively infects mature dendritic cells and alters their immune function J Virol 2003 77 4950 4959 12663800
Morrow G, Slobedman B, Cunningham AL, Abendroth A. Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol. 2003;77:4950–9.12663800
37. Nagel MA Gilden D Neurological complications of varicella zoster virus reactivation Curr Opin Neurol 2014 27 356 360 24792344
Nagel MA, Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol. 2014;27:356–60.24792344
38. Duan YW Chen SX Li QY Zang Y Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-α-necroptosis pathway Int J Mol Sci 2022 23 7191 35806192
Duan YW, Chen SX, Li QY, Zang Y. Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-α-necroptosis pathway. Int J Mol Sci. 2022;23:7191.35806192
39. Dutmer CM Asturias EJ Smith C Dishop MK Schmid DS Bellini WJ Tirosh I Lee YN Notarangelo LD Gelfand EW Late onset hypomorphic RAG2 deficiency presentation with fatal vaccine-strain VZV infection J Clin Immunol 2015 35 754 760 26515615
Dutmer CM, Asturias EJ, Smith C, Dishop MK, Schmid DS, Bellini WJ, Tirosh I, Lee YN, Notarangelo LD, Gelfand EW. Late onset hypomorphic RAG2 deficiency presentation with fatal vaccine-strain VZV infection. J Clin Immunol. 2015;35:754–60.26515615
40. Sen N Sommer M Che X White K Ruyechan WT Arvin AM Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses J Virol 2010 84 9240 9253 20631144
Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM. Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol. 2010;84:9240–53.20631144
41. Choi EJ Lee CH Shin OS Suppressor of cytokine signaling 3 expression induced by varicella-zoster virus infection results in the modulation of virus replication Scand J Immunol 2015 82 337 344 26072679
Choi EJ, Lee CH, Shin OS. Suppressor of cytokine signaling 3 expression induced by varicella-zoster virus infection results in the modulation of virus replication. Scand J Immunol. 2015;82:337–44.26072679
42. Bayat A Burbelo PD Browne SK Quinlivan M Martinez B Holland SM Buvanendran A Kroin JS Mannes AJ Breuer J Cohen JI Iadarola MJ Anti-cytokine autoantibodies in postherpetic neuralgia J Transl Med 2015 13 333 26482341
Bayat A, Burbelo PD, Browne SK, Quinlivan M, Martinez B, Holland SM, Buvanendran A, Kroin JS, Mannes AJ, Breuer J, Cohen JI, Iadarola MJ. Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med. 2015;13:333.26482341
43. Como CN Pearce CM Cohrs RJ Baird NL Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons Virology 2018 522 13 18 29979960
Como CN, Pearce CM, Cohrs RJ, Baird NL. Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons. Virology. 2018;522:13–8.29979960
44. Fei Y Huang B Deng J Xu L Yao M Efficacy of dorsal root ganglion pulsed radiofrequency combined with paravertebral injection of recombinant human interferon-α2b in herpetic neuralgia J Pain Res 2021 14 711 719 33732017
Fei Y, Huang B, Deng J, Xu L, Yao M. Efficacy of dorsal root ganglion pulsed radiofrequency combined with paravertebral injection of recombinant human interferon-α2b in herpetic neuralgia. J Pain Res. 2021;14:711–9.33732017
45. Chen YC Figliozzi RW Hsia SV Pilot analyses of interferon subtype expression profiles in patients with herpes zoster or postherpetic neuralgia Viral Immunol 2021 34 437 447 33857386
Chen YC, Figliozzi RW, Hsia SV. Pilot analyses of interferon subtype expression profiles in patients with herpes zoster or postherpetic neuralgia. Viral Immunol. 2021;34:437–47.33857386
46. Zhu SM Liu YM An ED Chen QL Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia J Zhejiang Univ Sci B 2009 10 625 630 19650202
Zhu SM, Liu YM, An ED, Chen QL. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10:625–30.19650202
47. Lin D Zhong C Jiang Q Huang A Liu Y Serum interleukin-6 levels are increased in post-herpetic neuralgia: a single-center retrospective study An Bras Dermatol 2023 98 202 207 36669977
Lin D, Zhong C, Jiang Q, Huang A, Liu Y. Serum interleukin-6 levels are increased in post-herpetic neuralgia: a single-center retrospective study. An Bras Dermatol. 2023;98:202–7.36669977
48. Fukuyasu A Kamata M SyHau C Nagata M Fukaya S Hayashi K Tanaka T Ishikawa T Ohnishi T Tada Y Kanda N Serum interleukin-10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia J Dermatol 2021 48 511 518 33609414
Fukuyasu A, Kamata M, SyHau C, Nagata M, Fukaya S, Hayashi K, Tanaka T, Ishikawa T, Ohnishi T, Tada Y, Kanda N. Serum interleukin-10 level increases in patients with severe signs or symptoms of herpes zoster and predicts the duration of neuralgia. J Dermatol. 2021;48:511–8.33609414
49. Khazan M Nasiri S Riahi SM Robati RM Hedayati M Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster J Med Virol 2020 92 1253 1259 30977905
Khazan M, Nasiri S, Riahi SM, Robati RM, Hedayati M. Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster. J Med Virol. 2020;92:1253–9.30977905
50. Liang X Fan Y Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk Front Immunol 2023 14 1183378 37304287
Liang X, Fan Y. Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk. Front Immunol. 2023;14:1183378.37304287
51. Fundaun JKolski M Molina-Álvarez M Baskozos G Schmid AB Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies: a systematic review and meta-analysis JAMA Netw Open 2022 5 e2248593 36574244
Fundaun J, Kolski M, Molina-Álvarez M, Baskozos G, Schmid AB. Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2248593.36574244
52. Zhong C Lin D Liu Y Wu C A retrospective study of the correlation between herpes zoster neuralgia and the serum neuron-specific enolase level in the largest dermatological hospital in Zhejiang province China Front Immunol 2022 13 972536 36275656
Zhong C, Lin D, Liu Y, Wu C. A retrospective study of the correlation between herpes zoster neuralgia and the serum neuron-specific enolase level in the largest dermatological hospital in Zhejiang province China. Front Immunol. 2022;13: 972536.36275656
53. Boggs JM Myelin basic protein: a multifunctional protein Cell Mol Life Sci 2006 63 1945 1961 16794783
Boggs JM. Myelin basic protein: a multifunctional protein. Cell Mol Life Sci. 2006;63:1945–61.16794783
54. Yang X Shen Y Ding Z Tian Y Hu J Guo Q Huang C Circulating level of myelin basic protein predicts postherpetic neuralgia: a prospective study Clin J Pain 2021 37 429 436 33883415
Yang X, Shen Y, Ding Z, Tian Y, Hu J, Guo Q, Huang C. Circulating level of myelin basic protein predicts postherpetic neuralgia: a prospective study. Clin J Pain. 2021;37:429–36.33883415
55. Wang T Fei Y Yao M Tao J Deng J Huang B Correlation between galectin-3 and early herpes zoster neuralgia and postherpetic neuralgia: a retrospective clinical observation Pain Res Manag 2020 2020 8730918 32351643
Wang T, Fei Y, Yao M, Tao J, Deng J, Huang B. Correlation between galectin-3 and early herpes zoster neuralgia and postherpetic neuralgia: a retrospective clinical observation. Pain Res Manag. 2020;2020:8730918.32351643
56. Sato M Ohashi J Tsuchiya N Kashiwase K Ishikawa Y Arita H Hanaoka K Tokunaga K Yabe T Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population Genes Immun 2002 3 477 481 12486606
Sato M, Ohashi J, Tsuchiya N, Kashiwase K, Ishikawa Y, Arita H, Hanaoka K, Tokunaga K, Yabe T. Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun. 2002;3:477–81.12486606
57. Sato-Takeda M Ihn H Ohashi J Tsuchiya N Satake M Arita H Tamaki K Hanaoka K Tokunaga K Yabe T The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster Pain 2004 110 329 336 15275783
Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, Tamaki K, Hanaoka K, Tokunaga K, Yabe T. The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain. 2004;110:329–36.15275783
58. Chung HY Song EY Yoon JA Suh DH Lee SC Kim YC Park MH Association of human leukocyte antigen with postherpetic neuralgia in Koreans APMIS 2016 124 865 871 27457498
Chung HY, Song EY, Yoon JA, Suh DH, Lee SC, Kim YC, Park MH. Association of human leukocyte antigen with postherpetic neuralgia in Koreans. APMIS. 2016;124:865–71.27457498
59. Meysman P Ogunjimi B Naulaerts S Beutels P Van Tendeloo V Laukens K Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia J Virol 2015 89 962 969 25355886
Meysman P, Ogunjimi B, Naulaerts S, Beutels P, Van Tendeloo V, Laukens K. Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia. J Virol. 2015;89:962–9.25355886
60. Zheng NN Zhang RC Yang XX Zhong LS Association of rs3783641 single-nucleotide polymorphism in GTP cyclohydrolase 1 gene with post-herpetic neuralgia J Dermatol 2019 46 993 997 31486149
Zheng NN, Zhang RC, Yang XX, Zhong LS. Association of rs3783641 single-nucleotide polymorphism in GTP cyclohydrolase 1 gene with post-herpetic neuralgia. J Dermatol. 2019;46:993–7.31486149
61. Mei Y Chen Q Li YP Chen YH Xia J Zeng J Yu LH Li W Cui J Genetic polymorphisms of PRKAA1 (AMPKα1) and postherpetic pain susceptibility: Multicenter, randomized control, and haplotype analysis study Front Mol Neurosci 2023 16 1128429 36818655
Mei Y, Chen Q, Li YP, Chen YH, Xia J, Zeng J, Yu LH, Li W, Cui J. Genetic polymorphisms of PRKAA1 (AMPKα1) and postherpetic pain susceptibility: Multicenter, randomized control, and haplotype analysis study. Front Mol Neurosci. 2023;16:1128429.36818655
62. Xing X Bai Y Sun K Chen Q Huang H Qiu W Yan M Identification of candidate genes associated with postherpetic neuralgia susceptibility Pain Physician 2020 23 E281 e288 32517404
Xing X, Bai Y, Sun K, Chen Q, Huang H, Qiu W, Yan M. Identification of candidate genes associated with postherpetic neuralgia susceptibility. Pain Physician. 2020;23:E281-e288.32517404
63. Nishizawa D Iseki M Arita H Hanaoka K Yajima C Kato J Ogawa S Hiranuma A Kasai S Hasegawa J Hayashida M Ikeda K Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia Mol Pain 2021 17 1744806921999924 33685280
Nishizawa D, Iseki M, Arita H, Hanaoka K, Yajima C, Kato J, Ogawa S, Hiranuma A, Kasai S, Hasegawa J, Hayashida M, Ikeda K. Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia. Mol Pain. 2021;17:1744806921999924.33685280
64. Zhou R Li J Zhang Y Xiao H Zuo Y Ye L Characterization of plasma metabolites and proteins in patients with herpetic neuralgia and development of machine learning predictive models based on metabolomic profiling Front Mol Neurosci 2022 15 1009677 36277496
Zhou R, Li J, Zhang Y, Xiao H, Zuo Y, Ye L. Characterization of plasma metabolites and proteins in patients with herpetic neuralgia and development of machine learning predictive models based on metabolomic profiling. Front Mol Neurosci. 2022;15:1009677.36277496
65. Lu L Mei L Li X Lin Y Wang H Yang G Metabolomics profiling in predicting of post-herpetic neuralgia induced by varicella zoster Sci Rep 2023 13 14940 37697028
Lu L, Mei L, Li X, Lin Y, Wang H, Yang G. Metabolomics profiling in predicting of post-herpetic neuralgia induced by varicella zoster. Sci Rep. 2023;13:14940.37697028
66. Oaklander AL Romans K Horasek S Stocks A Hauer P Meyer RA Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage Ann Neurol 1998 44 789 795 9818935
Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol. 1998;44:789–95.9818935
67. Oaklander AL The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles Pain 2001 92 139 145 11323135
Oaklander AL. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain. 2001;92:139–45.11323135
68. Rowbotham MC Yosipovitch G Connolly MK Finlay D Forde G Fields HL Cutaneous innervation density in the allodynic form of postherpetic neuralgia Neurobiol Dis 1996 3 205 214 8980021
Rowbotham MC, Yosipovitch G, Connolly MK, Finlay D, Forde G, Fields HL. Cutaneous innervation density in the allodynic form of postherpetic neuralgia. Neurobiol Dis. 1996;3:205–14.8980021
69. Fernández-Carvajal A Fernández-Ballester G Ferrer-Montiel A TRPV1 in chronic pruritus and pain: soft modulation as a therapeutic strategy Front Mol Neurosci 2022 15 930964 36117910
Fernández-Carvajal A, Fernández-Ballester G, Ferrer-Montiel A. TRPV1 in chronic pruritus and pain: soft modulation as a therapeutic strategy. Front Mol Neurosci. 2022;15: 930964.36117910
70. Hashimoto T Okuzawa M Yamamoto M Okuno S Satoh T Increased touch-evoked itch (punctate hyperknesis) in postherpetic itch: implications of reduced intraepidermal nerve fibers representing small fiber neuropathy J Dermatol 2023 50 393 396 36353761
Hashimoto T, Okuzawa M, Yamamoto M, Okuno S, Satoh T. Increased touch-evoked itch (punctate hyperknesis) in postherpetic itch: implications of reduced intraepidermal nerve fibers representing small fiber neuropathy. J Dermatol. 2023;50:393–6.36353761
71. Morris GC Gibson SJ Helme RD Capsaicin-induced flare and vasodilatation in patients with post-herpetic neuralgia Pain 1995 63 93 101 8577495
Morris GC, Gibson SJ, Helme RD. Capsaicin-induced flare and vasodilatation in patients with post-herpetic neuralgia. Pain. 1995;63:93–101.8577495
72. Rowbotham MC Fields HL Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature Pain 1989 39 129 144 2594392
Rowbotham MC, Fields HL. Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain. 1989;39:129–44.2594392
73. Kim HJ Yoon KB Kang M Yang YS Kim SH Subgrouping patients with zoster-associated pain according to sensory symptom profiles: a cluster analysis Front Neurol 2023 14 1137453 36873449
Kim HJ, Yoon KB, Kang M, Yang YS, Kim SH. Subgrouping patients with zoster-associated pain according to sensory symptom profiles: a cluster analysis. Front Neurol. 2023;14:1137453.36873449
74. Pappagallo M Oaklander AL Quatrano-Piacentini AL Clark MR Raja SN Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms Anesthesiology 2000 92 691 698 10719948
Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, Clark MR, Raja SN. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology. 2000;92:691–8.10719948
75. Baron R Haendler G Schulte H Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia Pain 1997 73 231 238 9415510
Baron R, Haendler G, Schulte H. Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia. Pain. 1997;73:231–8.9415510
76. Maier C Baron R Tölle TR Binder A Birbaumer N Birklein F Gierthmühlen J Flor H Geber C Huge V Krumova EK Landwehrmeyer GB Magerl W Maihöfner C Richter H Rolke R Scherens A Schwarz A Sommer C Tronnier V Üçeyler N Valet M Wasner G Treede DR Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes Pain 2010 150 439 450 20627413
Maier C, Baron R, Tölle TR, Binder A, Birbaumer N, Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V, Krumova EK, Landwehrmeyer GB, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Schwarz A, Sommer C, Tronnier V, Üçeyler N, Valet M, Wasner G, Treede DR. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439–50.20627413
77. Pfau DB Krumova EK Treede RD Baron R Toelle T Birklein F Eich W Geber C Gerhardt A Weiss T Magerl W Maier C Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): reference data for the trunk and application in patients with chronic postherpetic neuralgia Pain 2014 155 1002 1015 24525274
Pfau DB, Krumova EK, Treede RD, Baron R, Toelle T, Birklein F, Eich W, Geber C, Gerhardt A, Weiss T, Magerl W, Maier C. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): reference data for the trunk and application in patients with chronic postherpetic neuralgia. Pain. 2014;155:1002–15.24525274
78. Kramer S Baeumler P Geber C Fleckenstein J Simang M Haas L Schober G Pfab F Treede RD Irnich D Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia Pain 2019 160 882 894 30585985
Kramer S, Baeumler P, Geber C, Fleckenstein J, Simang M, Haas L, Schober G, Pfab F, Treede RD, Irnich D. Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia. Pain. 2019;160:882–94.30585985
79. Tang Y Wang M Zheng T Xiao Y Wang S Han F Chen G Structural and functional brain abnormalities in postherpetic neuralgia: a systematic review of neuroimaging studies Brain Res 2021 1752 147219 33358730
Tang Y, Wang M, Zheng T, Xiao Y, Wang S, Han F, Chen G. Structural and functional brain abnormalities in postherpetic neuralgia: a systematic review of neuroimaging studies. Brain Res. 2021;1752: 147219.33358730
80. Tang Y Ren C Wang M Dai G Xiao Y Wang S Han F Chen G Altered gray matter volume and functional connectivity in patients with herpes zoster and postherpetic neuralgia Brain Res 2021 1769 147608 34343527
Tang Y, Ren C, Wang M, Dai G, Xiao Y, Wang S, Han F, Chen G. Altered gray matter volume and functional connectivity in patients with herpes zoster and postherpetic neuralgia. Brain Res. 2021;1769: 147608.34343527
81. Liu J Gu L Huang Q Hong S Zeng X Zhang D Zhou F Jiang J Altered gray matter volume in patients with herpes zoster and postherpetic neuralgia J Pain Res 2019 12 605 616 30799946
Liu J, Gu L, Huang Q, Hong S, Zeng X, Zhang D, Zhou F, Jiang J. Altered gray matter volume in patients with herpes zoster and postherpetic neuralgia. J Pain Res. 2019;12:605–16.30799946
82. Liu X Gu L Liu J Hong S Luo Q Wu Y Yang J Jiang J MRI study of cerebral cortical thickness in patients with herpes zoster and postherpetic neuralgia J Pain Res 2022 15 623 632 35250306
Liu X, Gu L, Liu J, Hong S, Luo Q, Wu Y, Yang J, Jiang J. MRI study of cerebral cortical thickness in patients with herpes zoster and postherpetic neuralgia. J Pain Res. 2022;15:623–32.35250306
83. Huang J Li Y Xie H Yang S Jiang C Sun W Li D Liao Y Ba X Xiao L Abnormal intrinsic brain activity and neuroimaging-based fmri classification in patients with herpes zoster and postherpetic neuralgia Front Neurol 2020 11 532110 33192967
Huang J, Li Y, Xie H, Yang S, Jiang C, Sun W, Li D, Liao Y, Ba X, Xiao L. Abnormal intrinsic brain activity and neuroimaging-based fmri classification in patients with herpes zoster and postherpetic neuralgia. Front Neurol. 2020;11: 532110.33192967
84. Cao S Qin B Zhang Y Yuan J Fu B Xie P Song G Li Y Yu T Herpes zoster chronification to postherpetic neuralgia induces brain activity and grey matter volume change Am J Transl Res 2018 10 184 199 29423004
Cao S, Qin B, Zhang Y, Yuan J, Fu B, Xie P, Song G, Li Y, Yu T. Herpes zoster chronification to postherpetic neuralgia induces brain activity and grey matter volume change. Am J Transl Res. 2018;10:184–99.29423004
85. Cao S Li Y Deng W Qin B Zhang Y Xie P Yuan J Yu B Yu T Local brain activity differences between herpes zoster and postherpetic neuralgia patients: a resting-state functional MRI study Pain Physician 2017 20 E687 e699 28727713
Cao S, Li Y, Deng W, Qin B, Zhang Y, Xie P, Yuan J, Yu B, Yu T. Local brain activity differences between herpes zoster and postherpetic neuralgia patients: a resting-state functional MRI study. Pain Physician. 2017;20:E687-e699.28727713
86. Jiang J Huang Q Hong S Luo Q Liu X Hou X Gu L Diffusion tensor imaging study of the microstructural changes in the white matter of patients with herpes zoster and postherpetic neuralgia Am J Transl Res 2022 14 4350 4362 35836858
Jiang J, Huang Q, Hong S, Luo Q, Liu X, Hou X, Gu L. Diffusion tensor imaging study of the microstructural changes in the white matter of patients with herpes zoster and postherpetic neuralgia. Am J Transl Res. 2022;14:4350–62.35836858
87. Kim C Kim J Chang H Hong D Hong S Moon H Longitudinal change in brain functional connectivity with herpes zoster patients: neuroimaging case series Medicina (Kaunas) 2023 59 1045 37374249
Kim C, Kim J, Chang H, Hong D, Hong S, Moon H. Longitudinal change in brain functional connectivity with herpes zoster patients: neuroimaging case series. Medicina (Kaunas). 2023;59:1045.37374249
88. Wu Y Wang C Yu L Qian W Xing X Zhang M Yan M Abnormal within- and cross-networks functional connectivity in different outcomes of herpes zoster patients Brain Imaging Behav 2022 16 366 378 34549378
Wu Y, Wang C, Yu L, Qian W, Xing X, Zhang M, Yan M. Abnormal within- and cross-networks functional connectivity in different outcomes of herpes zoster patients. Brain Imaging Behav. 2022;16:366–78.34549378
89. Li J Gu L Hong S Chen Y Luo Q Wu Y Yang J Xiong J Lv H Jiang J Greater functional connectivity between the ventral frontal cortex and occipital cortex in herpes zoster patients than post-herpetic neuralgia patients Br J Radiol 2023 96 20220762 36341689
Li J, Gu L, Hong S, Chen Y, Luo Q, Wu Y, Yang J, Xiong J, Lv H, Jiang J. Greater functional connectivity between the ventral frontal cortex and occipital cortex in herpes zoster patients than post-herpetic neuralgia patients. Br J Radiol. 2023;96:20220762.36341689
90. Ko EJ No YA Park KY Li K Seo SJ Hong CK The clinical significance of infrared thermography for the prediction of postherpetic neuralgia in acute herpes zoster patients Skin Res Technol 2016 22 108 114 26081167
Ko EJ, No YA, Park KY, Li K, Seo SJ, Hong CK. The clinical significance of infrared thermography for the prediction of postherpetic neuralgia in acute herpes zoster patients. Skin Res Technol. 2016;22:108–14.26081167
91. Han SS Jung CH Lee SC Jung HJ Kim YH Does skin temperature difference as measured by infrared thermography within 6 months of acute herpes zoster infection correlate with pain level? Skin Res Technol 2010 16 198 201 20456100
Han SS, Jung CH, Lee SC, Jung HJ, Kim YH. Does skin temperature difference as measured by infrared thermography within 6 months of acute herpes zoster infection correlate with pain level? Skin Res Technol. 2010;16:198–201.20456100
92. Gewandter JS Dworkin RH Turk DC Farrar JT Fillingim RB Gilron I Markman JD Oaklander AL Polydefkis MJ Raja SN Robinson JP Woolf CJ Ziegler D Ashburn MA Burke LB Cowan P George SZ Goli V Graff OX Iyengar S Jay GW Katz J Kehlet H Kitt RA Kopecky EA Malamut R McDermott MP Palmer P Rappaport BA Rauschkolb C Steigerwald I Tobias J Walco GA Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations Pain 2015 156 1184 1197 25887465
Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, Markman JD, Oaklander AL, Polydefkis MJ, Raja SN, Robinson JP, Woolf CJ, Ziegler D, Ashburn MA, Burke LB, Cowan P, George SZ, Goli V, Graff OX, Iyengar S, Jay GW, Katz J, Kehlet H, Kitt RA, Kopecky EA, Malamut R, McDermott MP, Palmer P, Rappaport BA, Rauschkolb C, Steigerwald I, Tobias J, Walco GA. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain. 2015;156:1184–97.25887465
93. Makharita MY Prevention of post-herpetic neuralgia from dream to reality: a ten-step model Pain Physician 2017 20 E209 e220 28158158
Makharita MY. Prevention of post-herpetic neuralgia from dream to reality: a ten-step model. Pain Physician. 2017;20:E209-e220.28158158
94. Lin CS Lin YC Lao HC Chen CC Interventional treatments for postherpetic neuralgia: a systematic review Pain Physician 2019 22 209 228 31151330
Lin CS, Lin YC, Lao HC, Chen CC. Interventional treatments for postherpetic neuralgia: a systematic review. Pain Physician. 2019;22:209–28.31151330
95. Makharita MY Amr YM Effect of repeated paravertebral injections with local anesthetics and steroids on prevention of post-herpetic neuralgia Pain Physician 2020 23 565 572 33185373
Makharita MY, Amr YM. Effect of repeated paravertebral injections with local anesthetics and steroids on prevention of post-herpetic neuralgia. Pain Physician. 2020;23:565–72.33185373
96. Wu Q Hu H Han D Gao H Efficacy and safety of moxibustion for postherpetic neuralgia: a systematic review and meta-analysis Front Neurol 2021 12 676525 34512502
Wu Q, Hu H, Han D, Gao H. Efficacy and safety of moxibustion for postherpetic neuralgia: a systematic review and meta-analysis. Front Neurol. 2021;12: 676525.34512502
97. Lee DH Park JE Yoon DM Yoon KB Kim K Kim SH Factors associated with increased risk for clinical insomnia in patients with postherpetic neuralgia: a retrospective cross-sectional study Pain Med 2016 17 1917 1922 27073226
Lee DH, Park JE, Yoon DM, Yoon KB, Kim K, Kim SH. Factors associated with increased risk for clinical insomnia in patients with postherpetic neuralgia: a retrospective cross-sectional study. Pain Med. 2016;17:1917–22.27073226
98. Yamada K Kubota Y Shimizu Y Cui R Mori Y Okuno Y Asada H Yamanishi K Iso H Sleep shortage is associated with postherpetic neuralgia development through hyperesthesia and acute pain intensity: a community-based prospective cohort study Pain Pract 2019 19 476 483 30659740
Yamada K, Kubota Y, Shimizu Y, Cui R, Mori Y, Okuno Y, Asada H, Yamanishi K, Iso H. Sleep shortage is associated with postherpetic neuralgia development through hyperesthesia and acute pain intensity: a community-based prospective cohort study. Pain Pract. 2019;19:476–83.30659740
